Information non disponible
Management of Oligometastatic Breast Cancer: An Expert Committee's OpinionArticle de revue
Curr Oncol, 30 (2), 2023.
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN studyArticle de revue
Leukemia, 34 (2), 2020.
Evaluation of eligibility and recruitment in breast cancer clinical trialsArticle de revue
Breast, 23 (4), 2014.
Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patientsArticle de revue
Ann Pharmacother, 48 (4), 2014.
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 TrialArticle de revue
Blood, 121 (9), 2013.
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) GroupArticle de revue
Lancet Oncol, 12 (11), 2011.
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials GroupArticle de revue
J Clin Oncol, 29 (25), 2011.